Syed Ibrahim Bukhari: From Conventional Therapy to Gene-Based Approaches in Hemophilia Care
Syed Ibrahim Bukhari, Clinical Fellow at The Hospital for Sick Children, shared a post on LinkedIn:
“In honor of World Hemophilia Day 2025, I had the privilege of presenting on ‘Hemophilia Management: Current Standards and Emerging Frontiers’ at the National Institute of Child Health (NICH) in Karachi.
The session focused on the critical importance of specialized care for pediatric patients and the evolving landscape of treatment.
Key Highlights from the Presentation:
The Core Challenge: Hemophilia A and B are X-linked recessive disorders characterized by deficiencies in clotting factors VIII and IX, respectively, leading to prolonged bleeding and potential joint damage.
Diagnosis and Severity: We discussed the importance of classifying severity based on factor levels—Severe (<1 percent), Moderate (1-5 percent), and Mild (5-40 percent)—to tailor treatment effectively.
Management Pillars: The talk emphasized the ‘P.R.I.C.E’ protocol for acute bleeds (Protection, Rest, Ice, Compression, Elevation) alongside prompt factor replacement therapy.
Prophylaxis versus Episodic Care: A major focus was the shift toward prophylaxis (regular treatment to prevent bleeds) as the gold standard for preventing chronic hemophilic arthropathy and improving quality of life.
Inhibitors and Complications: We addressed the challenge of inhibitors, where the body’s immune system reacts against replacement factors, necessitating advanced bypass agents or immune tolerance induction.
Future Frontiers: I shared insights into the potential of gene therapy and non-factor replacement therapies, like Emicizumab, which are revolutionizing how we approach long-term care.
Thank you to the team at NICH for organizing this event and for their unwavering commitment to our young patients in Karachi.
Together, we can strive for a future where ‘Access for All’ becomes a reality.”

See more in the gallery.
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support